Did the FDA approve atezolizumab for stage III dMMR colon cancer?

Yes. The article says the FDA approved both intravenous and subcutaneous atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III mismatch repair deficient (dMMR) colon cancer, based on the ATOMIC trial. It highlights this as another signal of biomarker-defined treatment expansion in earlier-line oncology.